PATENT CLAIM ANALYSIS

Application Number: 16172312
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "314000"]

Abstract:
The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claim (Index 5):
The compound of  claim 1 , wherein Ar 1 , when present, is selected from aryl and heteroaryl and is substituted with 1-4 non-hydrogen groups independently selected from halogen, \u2014CN, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, \u2014(CH 2 ) m NH 2 , \u2014(CH 2 ) m (C1-C4 alkylamino), \u2014(CH 2 ) m [(C1-C4)(C1-C4) dialkylamino], \u2014(CH 2 ) m NH(C\u2550O)(C1-C4 alkyl), \u2014(CH 2 ) m N(C1-C4 alkyl)(C\u2550O)(C1-C4 alkyl), and Cy 5 .

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.41176
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15892302', '14913266', '14380659', '13974858', '15039763']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8222462391348943
- 35 USC 102 Novelty (BERT): 0.6143477636377488
- Combined Prediction Score: 0.8014563915851798
- Mean Citation Score: 518.051642
- Max Citation Score: 573.8161
- Similarity Product: 479.01169611101153

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test